Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Clinical trial NCT04938817 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04938817
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-19
- Primary completion
- 2029-12-10
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.